How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

681 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

221. Desvenlafaxine Monotherapy in Dysthymia

Disorder, provided that Dysthymic Disorder is currently the diagnosis). Meet DSM-IV criteria for a current episode of major depression within two months prior to screening or who have received treatment for a major depressive episode within six months prior to screening. Substance abuse or dependence including alcohol, within 6 months prior to screening. Patients on the following prohibited treatments: Psychotropics such as other SSRIs, other SNRIs, lithium, sibutramine, tramadol, St. John's Wort

2013 Clinical Trials

222. Pharmacological interventions for weight loss: a review of the clinical and cost-effectiveness

database. Citation Mujoomdar M, Spry C. Pharmacological interventions for weight loss: a review of the clinical and cost-effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2009 Authors' conclusions Overall, all of the included studies that assessed the clinical effectiveness of either orlistat or sibutramine demonstrated that both drugs were capable of promoting weight loss. These two studies concluded that sibutramine was more effective than orlistat. With respect (...) to adverse events, reporting was inconsistent throughout studies, but typically orlistat was associated with gastrointestinal disturbances and several reports suggested that sibutramine might increase blood pressure and heart rate. Indeed adverse reactions have been reported to Health Canada in patients with a history of cardiovascular disease, those with unstable or uncontrolled hypertension, and other contraindicated conditions. Two studies reported that treatment with either orlistat or sibutramine

2009 Health Technology Assessment (HTA) Database.

223. Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. Full Text available with Trip Pro

Association of hypoglycemic treatment regimens with cardiovascular outcomes in overweight and obese subjects with type 2 diabetes: a substudy of the SCOUT trial. To assess the association of hypoglycemic treatment regimens with cardiovascular adverse events and mortality in a large population of type 2 diabetic patients at increased cardiovascular risk.This analysis included 8,192 overweight patients with type 2 diabetes from the Sibutramine Cardiovascular Outcomes (SCOUT) trial randomized (...) to lifestyle intervention with or without sibutramine for up to 6 years. Patients were grouped according to hypoglycemic treatment at baseline. The primary end point was the time from randomization to the first occurrence of a primary outcome event (POE), nonfatal myocardial infarction, nonfatal stroke, resuscitation after cardiac arrest, or cardiovascular death. Multivariable Cox proportional hazards regression models were used to assess the impact of antiglycemic treatment on POE and all-cause

2013 Diabetes Care Controlled trial quality: uncertain

224. Association of anemia with the risk of cardiovascular adverse events in overweight/obese patients. (Abstract)

overweight/obese cardiovascular high-risk patients from the Sibutramine Cardiovascular OUTcomes trial were studied. Patients were stratified after baseline hemoglobin level and followed for the risks of primary event (comprising nonfatal myocardial infarction, nonfatal stroke, resuscitated cardiac arrest or cardiovascular death) and all-cause mortality. Risk estimates (hazard ratios (HR) with 95% confidence intervals (CI)) were calculated using Cox regression models.Anemia was unadjusted associated

2013 International Journal of Obesity Controlled trial quality: uncertain

225. Palatability (Energy I Pilot)

use prescriptions or over-the-counter medications or herbal products that affect metabolism or body weight (e.g. weight loss medications such as sibutramine, or orlistat). You have symptoms of depression or excessive dietary restraint. You have an allergy to one or more of the test foods. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided

2012 Clinical Trials

226. Positive Energy I Through Overfeeding

, appetite, or metabolism, such as diabetes and cardiovascular disease. You have irregular menstrual cycles, had a partial hysterectomy (still maintain ovaries), or use an IUD not made of copper. You use prescriptions or over-the-counter medications or herbal products that affect metabolism or body weight (e.g. weight loss medications such as sibutramine, or orlistat). You use a birth control pill that isn't monophasic or you receive Depro-Provera injections. You have barriers to completing the study

2012 Clinical Trials

227. Effect on Liver Histology of Vitamin D in Patients With Non-alcoholic Steatohepatitis

, sibutramine. Oral hypoglycaemic agents and insulin will be allowed, provided they had been initiated at least 6 months before enrollment and are maintained at stable doses. Ongoing or recent therapy (within 6 months of baseline liver biopsy and screening visit) with vitamin D or with medications known to affect vitamin D3 metabolism, including vitamin/mineral supplements. Any additional condition that might interfere with optimal participation in the study, according to Investigators opinion. Be pregnant

2012 Clinical Trials

228. Slowing HEART diSease With Lifestyle and Omega-3 Fatty Acids

for weight loss [eg Xenical (orlistat), Meridia (sibutramine), Acutrim (phenylpropanolamine) or similar over-the-counter medications] within three months of screening surgery within 30 days of screening history of acquired immune deficiency syndrome or human immunodeficiency virus (HIV) poor mental function or history of dementia/Alzheimer's Disease or on medications used for treatment of dementia [e.g. Tacrine (Cognex), Rivastigmine (Exelon), Galantamine (Razadyne, Reminyl), Donepezil (Aricept

2012 Clinical Trials

229. The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity

artery disease (e.g. angina, myocardial infraction); congestive heart failure; tachycardia; peripheral arterial occlusive disease; arrythmia; Uncontrolled arterial hypertension >145/90 mm Hg; Hypersensitivity to sibutramine or any components of Reduxine®; Current use of monoamineoxidase inhibitors (IMAO) or their use within the last 2 weeks; Current use of other central acting weight reducing drugs or their use within the last 2 weeks; Use on other drugs affecting the central nervous system (e.g

2012 Clinical Trials

230. Domperidone for the Treatment of Chronic Nausea and Vomiting Secondary to Gastroparesis

, moxifloxacin, nilotinib, norepinephrine, ondansetron, oxytocin, paliperidone, perflutren lipid microspheres, phentermine, phenylephrine, phenylpropanolamine, protriptyline, pseudoephedrine, ranolazine, ritodrine, toxithromycin, sibutramine, solifenacin, sunitinib, tacrolimus, telithromycin, terbutaline, terfenadine, tolterodine, trimethoprim-sulfa, vandetanib, vardenafil, voriconazole. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your

2012 Clinical Trials

231. Evaluating the Health Benefits of Physical Activity Recommendations in the Dietary Guidelines

10 lbs in the preceding 6 months Medications: chronic corticosteroid use or need for oral corticosteroids more than twice in the last 12 months, antipsychotic medications, beta adrenergic blockers, medications for weight loss (including sibutramine, orlistat, phentermine, phendimetrazine, topiramate, zonisamide), immunosuppressants, amphetamines and other stimulants, and other medications known to influence body weight Travel plans that do not permit full participation Contacts and Locations Go

2012 Clinical Trials

232. Satiety Innovation- Study 793. University of Aberdeen

, history of gastric bezoar. Suspected strictures, fistulas, or physiological GI obstruction. Psychiatric disorder: severe depression, bulimia, anorexia, schizophrenia, bipolar disorder. Gastrointestinal procedure or surgery in the past three months. Disorders of swallowing, severe dysphagia to food or pills. Pregnancy Medication exclusion criteria Appetite modulator drugs: orlistat, sibutramine, rimonabant. Mood disorder medications: antidepressants, lithium. Others: oral antidiabetics, insulin

2012 Clinical Trials

233. Assessment of Energy Balance

an 8 week weight loss diet, consisting of supplement or powdered shakes, portion-controlled entrees, or home-cooked meals. Exclusion Criteria: A diagnosis of diabetes, cardiovascular disease, or cancer. Females who are pregnant or planning to become pregnant during the trail. Medications that influence appetite or body weight (weight loss medications such as sibutramine, antipsychotic medications such as olanzapine, or herbal weight loss products) taken during the previous three months. Contacts

2012 Clinical Trials

234. Toxicity of Weight Loss Agents Full Text available with Trip Pro

, phenylpropanolamine, ma huang/ ephedra, caffeine, clenbuterol, fenfluramine, sibutramine, thyroid hormone, orlistat and cannabinoid antagonists.With the internet making even banned products readily accessible, healthcare providers need to be aware of the potential toxicities of a wide range of weight loss agents. Our review covered topics we thought to be most historically significant as well as pertinent to the practice of medical toxicology today.

2012 Journal of Medical Toxicology

235. Placebo Controlled Trial of Dextromethorphan in Rett Syndrome

medical illnesses such as vasculopathies, malignancies, diabetes, thyroid dysfunction, etc; those on medications that could interact with DM, e.g. MAO inhibitors, SSRI, sibutramine etc. to avoid a serotonin syndrome; quinidine and drugs metabolized by the CYP450 isoform CYP2D6 (e.g. amiodarone, haloperidol, propafenone, thioridazine); those proven to be intermediate or slow metabolizers of DM; those with reported adverse reactions to DM; those whose pregnancy test is positive; those showing poor

2012 Clinical Trials

236. Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALE™

of the investigator Glycosylated haemoglobin (HbA1c) equal to or above 6.5% Significant craniofacial abnormalities that may cause OSA Respiratory and neuromuscular diseases that could interfere with the results of the trial in the opinion of the investigator Use of central stimulants, hypnotics, mirtazepine, opioids, trazodone within the previous 3 months prior to screening Obesity induced by drug treatment Treatment with pramlintide, sibutramine, orlistat, zonisamide, topiramate or phenteremine within the last 3

2012 Clinical Trials

237. Proof of Concept Trial of Gleevec (Imatinib) in Active Diffuse Scleroderma

<1.5X109/L, platelets < 50X109/L. Serious comorbidity that may impair the ability to complete the study (such as severe heart disease, severe pulmonary hypertension) and other comorbidities. Prednisone at doses of >10mg/od. Other potential disease modifying drugs such as cyclophosphamide, mycophenylate and methotrexate. Serious liver disease. Creatinine >200. Excluded: Ketoconazole and fluconazole, cyclosporine, rifampin, phenytoin nefazodone, pimozide, propafenone, quinidine, sibutramine

2012 Clinical Trials

238. Intragastric balloon in association with lifestyle and/or pharmacotherapy in the long-term management of obesity. (Abstract)

in sequence as a maintenance strategy for weight loss.Fifty obese patients were recruited and randomly assigned to lifestyle modifications combined with either BIB for 6 months (n = 30) or sibutramine (pharmacotherapy group) for 1 year (n = 20). After BIB removal, patients were randomly assigned to either correct lifestyle (BIB/lifestyle) or lifestyle plus pharmacotherapy (BIB/pharmacotherapy).At 6 months, patients treated with BIB lost significantly (P < 0.05) more weight (percent of initial weight lost

2012 Obesity Surgery Controlled trial quality: uncertain

239. Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. (Abstract)

Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine. This was followed by 12 weeks of observation. The best of the "baseline covariates" models was one that incorporated intervention

2012 Clinical pharmacology and therapeutics Controlled trial quality: uncertain

240. Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. Full Text available with Trip Pro

Relationship between HbA1c levels and risk of cardiovascular adverse outcomes and all-cause mortality in overweight and obese cardiovascular high-risk women and men with type 2 diabetes. The optimal HbA(1c) concentration for prevention of macrovascular complications and deaths in obese cardiovascular high-risk patients with type 2 diabetes remains to be established and was therefore studied in this post hoc analysis of the Sibutramine Cardiovascular OUTcomes (SCOUT) trial, which enrolled

2012 Diabetologia Controlled trial quality: uncertain

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>